Cite
HARVARD Citation
Saumoy, M. et al. (2022). Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. Journal of antimicrobial chemotherapy. pp. 1980-1988. [Online].